Database Query Results : , ,

RCC, Renal cell Carcinoma: Click to Expand ⟱
Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system, accounting for 80–90% of kidney neoplasms.
The activation of the mTOR pathway has been found in RCC and is correlated with high grade and poor prognostic patient features (41,42).
Scientific Papers found: Click to Expand⟱
310- Api,    Apigenin inhibits renal cell carcinoma cell proliferation
- vitro+vivo, RCC, ACHN - in-vitro, RCC, 786-O - in-vitro, RCC, Caki-1 - in-vitro, RCC, HK-2
TumCCA↑, p‑ATM↑, p‑CHK1↑, p‑CDC25↑, p‑cDC2↑, P53↑, BAX↑, Casp9↑, Casp3↑,
3179- Ash,    Withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells
- in-vitro, RCC, Caki-1
JAK↓, STAT3↓, Apoptosis↑,
1374- BBR,  PDT,    Berberine associated photodynamic therapy promotes autophagy and apoptosis via ROS generation in renal carcinoma cells
- in-vitro, RCC, 786-O - in-vitro, RCC, HK-2
ROS↑, TumAuto↑, Apoptosis↑, Casp3↑, eff↑,
1426- Bos,  CUR,  Chemo,    Novel evidence for curcumin and boswellic acid induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer
- in-vivo, CRC, NA - in-vitro, CRC, HCT116 - in-vitro, CRC, RKO - in-vitro, CRC, SW480 - in-vitro, RCC, SW-620 - in-vitro, RCC, HT-29 - in-vitro, CRC, Caco-2
miR-34a↑, miR-27a-3p↓, TumCG↓, BAX↑, Bcl-2↓, PARP1↓, TumCCA↑, Apoptosis↑, cMyc↓, CDK4↓, CDK6↓, cycD1/CCND1↓, ChemoSen↑, miR-34a↑, miR-27a-3p↓,
2799- CHr,    Chrysin suppresses renal carcinogenesis via amelioration of hyperproliferation, oxidative stress and inflammation: plausible role of NF-κB
- in-vivo, RCC, NA
*chemoPv↑, *ROS↓, *Inflam↓,
988- EMD,    Emodin Induced Necroptosis and Inhibited Glycolysis in the Renal Cancer Cells by Enhancing ROS
- in-vitro, RCC, NA
Necroptosis↑, p‑RIP1↑, MLKL↑, ROS↑, Glycolysis↓, GLUT1↓, PI3K↓, Akt↓,
1289- FA,    Cytotoxic and Apoptotic Effects of Ferulic Acid on Renal Carcinoma Cell Line (ACHN)
- in-vitro, RCC, NA
Bcl-2↓, BAX↑, Apoptosis↑,
2855- FIS,    Fisetin Induces Apoptosis Through p53-Mediated Up-Regulation of DR5 Expression in Human Renal Carcinoma Caki Cells
- in-vitro, RCC, Caki-1
TumCCA↑, cl‑PARP↑, Apoptosis↑, Casp↑, P53↑, DR5↑, CHOP↑, ROS↑, ER Stress↑, ATF4↑, XBP-1↑, eff∅,
794- GAR,    Garcinol Enhances TRAIL-Induced Apoptotic Cell Death through Up-Regulation of DR5 and Down-Regulation of c-FLIP Expression
- in-vitro, RCC, NA - in-vitro, Lung, A549 - in-vitro, Nor, NA
DR5↑, cFLIP↓, *toxicity↓,
1120- HNK,    Honokiol suppresses renal cancer cells' metastasis via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties through modulating miR-141/ZEB2 signaling
- vitro+vivo, RCC, NA
EMT↓, CSCs↓, TumCG↓, miR-141↑,
1004- HNK,  RAPA,    Honokiol downregulates PD-L1 expression and enhances antitumor effects of mTOR inhibitors in renal cancer cells
- in-vitro, RCC, NA
Apoptosis↑, TumCCA↑, ROS↑, PD-L1↓, IFN-γ↓,
4688- HNK,    Honokiol Suppresses Renal Cancer Cells’ Metastasis via Dual-Blocking Epithelial-Mesenchymal Transition and Cancer Stem Cell Properties through Modulating miR-141/ZEB2 Signaling
- vitro+vivo, RCC, A498
CSCs↓, EMT↓, TumCG↓, PI3K↓, Akt↓, mTOR↓, p‑Akt↓, PTEN↑, Wnt↓, β-catenin/ZEB1↓,
863- Lae,    Amygdalin inhibits the growth of renal cell carcinoma cells in vitro
- in-vitro, RCC, NA
TumCG↓, TumCP↓, TumCCA↑, CDK1↓, CycB/CCNB1↓, E-cadherin↝, N-cadherin↝,
2383- MET,    Activation of AMPK by metformin promotes renal cancer cell proliferation under glucose deprivation through its interaction with PKM2
- in-vitro, RCC, A498
AMPK↑, TumCP↓, eff↓, eff↑,
1762- MF,  Fe,    Triggering the apoptosis of targeted human renal cancer cells by the vibration of anisotropic magnetic particles attached to the cell membrane
- in-vitro, RCC, NA
Dose∅, Apoptosis↑, Casp↑, tumCV↓, Casp3↑, Casp7↑, Ca+2↑, Cyt‑c↑,
885- RES,    Resveratrol induces intracellular Ca2 + rise via T-type Ca2 + channels in a mesothelioma cell line
- in-vitro, RCC, REN - in-vitro, Nor, MeT5A
TumCG↓, Ca+2↑, *toxicity↓,
3070- RES,    Resveratrol inhibits tumor progression by down-regulation of NLRP3 in renal cell carcinoma
- in-vitro, RCC, ACHN - in-vitro, RCC, 786-O - in-vivo, NA, NA
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, NLRP3↓,
109- SIL,    Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma
- vitro+vivo, RCC, 769-P - in-vitro, RCC, 786-O - in-vitro, RCC, ACHN - in-vitro, RCC, OS-RC-2
HH↓, Gli1↓, GLI2↓, mTOR↓, Bcl-2↓,
3403- TQ,    A multiple endpoint approach reveals potential in vitro anticancer properties of thymoquinone in human renal carcinoma cells
- in-vitro, RCC, 786-O
tumCV↓, ROS↑, TumCCA↑, eff↓, TumCI↓,
3414- TQ,    Thymoquinone induces apoptosis through inhibition of JAK2/STAT3 signaling via production of ROS in human renal cancer Caki cells
- in-vitro, RCC, Caki-1
tumCV↓, Apoptosis↑, P53↑, BAX↑, Cyt‑c↑, cl‑Casp9↑, cl‑Casp3↑, cl‑PARP↑, Bcl-2↓, Bcl-xL↓, p‑STAT3↓, p‑JAK2↓, STAT3↓, survivin↓, cycD1/CCND1↓, ROS↑, eff↓,
2125- TQ,    Thymoquinone Selectively Kills Hypoxic Renal Cancer Cells by Suppressing HIF-1α-Mediated Glycolysis
- in-vitro, RCC, RCC4 - in-vitro, RCC, Caki-1
Hif1a↓, eff↝, uPAR↓, VEGF↓, CAIX↓, PDK1↓, GLUT1↓, LDHA↓, Glycolysis↓, e-lactateProd↓, i-ATP↓,
3119- VitC,    Ascorbic acid–induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma
- in-vitro, RCC, NA
TET2↑, TumCG↓, tumCV↓,
3121- VitC,  immuno,    Ascorbic acid induced TET2 enzyme activation enhances cancer immunotherapy efficacy in renal cell carcinoma
- in-vivo, RCC, A498 - in-vitro, RCC, 786-O
TET2↑, eff↑, eff↑,
3138- VitC,    The Hypoxia-inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-induced Toxicity
- in-vitro, RCC, RCC4 - in-vitro, CRC, HCT116 - in-vitro, BC, MDA-MB-435 - in-vitro, Ovarian, SKOV3 - in-vitro, Colon, SW48 - in-vitro, GBM, U251
eff↑, Warburg↓, BioAv↑, ROS↑, DNAdam↑, ATP↓, eff↑, necrosis↑, PARP↑,
115- VitD3,    Vitamin D3 triggers antitumor activity through targeting hedgehog signaling in human renal cell carcinoma Vitamin D3 Inhibits Hedgehog Signaling and Proliferation in Murine Basal Cell Carcinomas
- in-vivo, RCC, NA - in-vivo, BCC, NA
HH↓, GLI2↓, Shh↓, Gli1↓,
961- Z,    Zinc Downregulates HIF-1α and Inhibits Its Activity in Tumor Cells In Vitro and In Vivo
- in-vitro, RCC, RCC4 - vitro+vivo, GBM, U373MG - in-vitro, Nor, HUVECs
Hif1a↓, HIF-1↓, VEGF↓, TumCI↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 26

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 7,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   i-ATP↓, 1,   p‑CDC25↑, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   CAIX↓, 1,   cMyc↓, 1,   Glycolysis↓, 2,   e-lactateProd↓, 1,   LDHA↓, 1,   PDK1↓, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 2,   p‑Akt↓, 1,   Apoptosis↑, 9,   BAX↑, 4,   Bcl-2↓, 4,   Bcl-xL↓, 1,   Casp↑, 2,   Casp3↑, 3,   cl‑Casp3↑, 1,   Casp7↑, 1,   Casp9↑, 1,   cl‑Casp9↑, 1,   cFLIP↓, 1,   Cyt‑c↑, 2,   DR5↑, 2,   MLKL↑, 1,   Necroptosis↑, 1,   necrosis↑, 1,   p‑RIP1↑, 1,   survivin↓, 1,  

Transcription & Epigenetics ⓘ

miR-27a-3p↓, 2,   tumCV↓, 4,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   ER Stress↑, 1,   XBP-1↑, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 1,  

DNA Damage & Repair ⓘ

p‑ATM↑, 1,   p‑CHK1↑, 1,   DNAdam↑, 1,   P53↑, 3,   PARP↑, 1,   cl‑PARP↑, 2,   PARP1↓, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK4↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 2,   TumCCA↑, 6,  

Proliferation, Differentiation & Cell State ⓘ

p‑cDC2↑, 1,   CSCs↓, 2,   EMT↓, 2,   Gli1↓, 2,   HH↓, 2,   miR-34a↑, 2,   mTOR↓, 2,   PI3K↓, 2,   PTEN↑, 1,   Shh↓, 1,   STAT3↓, 2,   p‑STAT3↓, 1,   TumCG↓, 6,   Wnt↓, 1,  

Migration ⓘ

Ca+2↑, 2,   E-cadherin↝, 1,   GLI2↓, 2,   miR-141↑, 1,   N-cadherin↝, 1,   TumCI↓, 3,   TumCMig↓, 1,   TumCP↓, 3,   uPAR↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

ATF4↑, 1,   HIF-1↓, 1,   Hif1a↓, 2,   VEGF↓, 2,  

Barriers & Transport ⓘ

GLUT1↓, 2,  

Immune & Inflammatory Signaling ⓘ

IFN-γ↓, 1,   JAK↓, 1,   p‑JAK2↓, 1,   PD-L1↓, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   ChemoSen↑, 1,   Dose∅, 1,   eff↓, 3,   eff↑, 6,   eff↝, 1,   eff∅, 1,   TET2↑, 2,  

Clinical Biomarkers ⓘ

PD-L1↓, 1,  
Total Targets: 94

Pathway results for Effect on Normal Cells:


NA, unassigned ⓘ

chemoPv↑, 1,  

Redox & Oxidative Stress ⓘ

ROS↓, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  

Functional Outcomes ⓘ

toxicity↓, 2,  
Total Targets: 4

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:24  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page